InsidersTradesSigma
Follow the 昊帆生物 share price and the full management transaction log of the company, a listed issuer based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 昊帆生物 has logged 10 public disclosures. Market capitalisation: €6.1bn. The latest transaction was disclosed on 18 July 2024 (Purchase). Among the most active insiders: 徐杰. Every trade is free.
10
Insider Decl.
n/a
Thresholds
€1m
10 ops.
Buy Volume
n/a
n/a
Sell Volume
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,339 of 29,056 companies
46.2
score / 100
Value27
Quality65
FCF yld-2.2%
Earn yld1.9%
EV/EBITDA36.8x
ROE4.6%
Gross mgn35%
Net mgn19%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 July 2024
Declarations10 total
10 of 10 declarations
About 昊帆生物
昊帆生物 is a company focused on the health and pharmaceutical sector, specializing in the development of biopharmaceutical products. It is listed on the XSHE market.